Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Schaeffer Orlov S Nicole	2. Issuer Name and Ticker or Trading Symbol INSMED Inc [ INSM ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief People Strategy Officer
(Last) (First) (Middle) 700 US HIGHWAY 202/206	3. Date of Earliest Transaction (MM/DD/YYYY) 5/15/2020
(Street) BRIDGEWATER, NJ 08807 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock ⁽¹⁾	5/15/2020		F		1126	D	$25.46	35227	D
Common Stock	8/11/2020		M		3761	A	$6.96	38988	D
Common Stock	8/11/2020		S		3761	D	$30.07 ⁽²⁾	35227	D
Common Stock	8/12/2020		M		465	A	$6.96	35692	D
Common Stock	8/12/2020		S		465	D	$28.77 ⁽³⁾	35227	D
Common Stock	8/12/2020		M		4000	A	$12.44	39227	D
Common Stock	8/12/2020		S		4000	D	$28.80 ⁽⁴⁾	35227	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$6.96	8/11/2020		M			3761	⁽⁵⁾	1/2/2023	Common Stock	3761	$0	465	D
Stock Option (right to buy)	$6.96	8/12/2020		M			465	⁽⁵⁾	1/2/2023	Common Stock	465	$0	0	D
Stock Option (right to buy)	$12.44	8/12/2020		M			4000	⁽⁶⁾	5/23/2023	Common Stock	4000	$0	8500	D

Explanation of Responses:
(1)	Represents the withholding of shares of common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units. This transaction was not reported previously due to a clerical error.
(2)	This is the weighted average sales price representing 3,761 shares sold at prices ranging from $30.00 to $30.45 per share. The number sold at each price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.
(3)	This is the weighted average sales price representing 465 shares sold at prices ranging from $28.75 to $28.79 per share. The number sold at each price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.
(4)	This is the weighted average sales price representing 4,000 shares sold at prices ranging from $28.71 to $28.95 per share. The number sold at each price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.
(5)	The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
(6)	On May 23, 2013, the reporting person was granted an option to purchase 25,000 shares of common stock. The option vests in two installments based upon the Issuer's satisfaction of two separate performance metrics. The first installment vested on February 26, 2015. The performance metric applicable to the second installment, the first written approval of a New Drug Application or Marketing Authorization Application from the Food and Drug Administration of European Medicines Agency, respectively, was met on September 28, 2018, resulting in the vesting of the second installment.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Schaeffer Orlov S Nicole 700 US HIGHWAY 202/206 BRIDGEWATER, NJ 08807			Chief People Strategy Officer